News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

Elan Corporation PLC (ELN) Issues Response Document Further Detailing Inadequacy of Royalty Pharma's Revised Offer



6/3/2013 10:31:40 AM

Staying up-to-date has never been simpler. Sign up for the free GenePool newsletter today!

DUBLIN--(BUSINESS WIRE)--Elan Corporation, plc (NYSE: ELN) today issued a formal response document in respect of the Echo Pharma Acquisition Limited (Royalty Pharma) revised offer made on May 23, 2013. The response document is available on Elan’s website at www.elan.com. The response document details why Elan believes Royalty Pharma’s current offer of $12.50 per share substantially undervalues Elan, and how Elan’s recently announced transactions further widen the gap between Royalty Pharma’s undervalued offer and the fair value of Elan shares.

Help employers find you! Check out all the jobs and post your resume.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES